The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes
Clinicaltrials.gov identifier:
NCT04171700
Study Contact Information:
Principal Investigator:
Kim Reiss-Binder, MD
University of Pennsylvania
A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)
About the Study
The LODESTAR study is evaluating the response of the rucaparib in people with advanced (including breast, ovarian, pancreatic, and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: , , , , , , , FANCA, , RAD51 or RAD51B. NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.